RXO
RXO, Inc.
RXO lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
RXO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Weak |
RXO's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
RXO PE Valuation
RXO has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 54x next year's earnings.
RXO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect RXO to return to profit, with revenue growing. However, they disagree widely on these estimates.
RXO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.52 | — |
| Q3 2026 | -$0.52 | -$0.04 |
| Q2 2026 | -$0.62 | +$1.59 |
| Q1 2026 | -$0.62 | +$1.60 |
| Q4 2025 | -$0.59 | +$1.58 |
| Q3 2025 | -$0.48 | +$1.51 |
| Q2 2025 | -$2.21 | -$2.02 |
| Q1 2025 | -$2.22 | -$2.12 |
| Q4 2024 | -$2.17 | -7333% |
RXO is still losing money, but far less than before: $0.52 per share over the past year, against $2.22 at its worst in early 2025.
RXO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +32% |
| Q2 2026 | $1.8B | +25% |
| Q1 2026 | $1.4B | -0.6% |
| Q4 2025 | $1.5B | -12% |
| Q3 2025 | $1.4B | +37% |
| Q2 2025 | $1.4B | +53% |
| Q1 2025 | $1.4B | +57% |
| Q4 2024 | $1.7B | +70% |
RXO's revenue is growing: $1.9B last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.9% | +1.4 points |
| Q2 2026 | 0.1% | +0.1 points |
| Q1 2026 | -2% | +0.1 points |
| Q4 2025 | -2.9% | -1.4 points |
| Q3 2025 | -0.5% | +1.4 points |
| Q2 2025 | 0% | 0 points |
| Q1 2025 | -2.1% | -0.8 points |
| Q4 2024 | -1.4% | -2.9 points |
RXO's operating margin was 0.9% last quarter, up 1.4 points from the same quarter a year ago.
RXO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12M | +33% |
| Q2 2026 | -$52M | -678% |
| Q1 2026 | -$24M | -$7M |
| Q4 2025 | -$9M | +$10M |
| Q3 2025 | $9M | +$27M |
| Q2 2025 | $9M | +$25M |
| Q1 2025 | -$17M | -$13M |
| Q4 2024 | -$19M | -2000% |
RXO's free cash flow was −$73M over the past year, against −$18M the year before.
RXO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.4% | +2.4M shares |
| 1 year | +2% | +3.4M shares |
| 3 years | +47% | +55M shares |
| 5 years | +49% | +56.9M shares |
RXO has 172M diluted shares, up 2% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
RXO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.4x | High |
| Q2 2026 | 16.0x | High |
| Q1 2026 | 12.9x | High |
| Q4 2025 | 10.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 9.2x | High |
| Q1 2025 | 13.4x | High |
| Q4 2024 | 10.7x | High |
RXO's net debt is about 8.4 years of its operating earnings (EBITDA), up from 6.3 years a year ago.
RXO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.7 | Neutral |
| Stochastic | 85.5 | Overbought |
RXO's weekly RSI is 61 (neutral) and its Stochastic is 85 (overbought).
RXO PE vs Industrials Sector
| Metric | RXO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
RXO has no meaningful PE right now: it lost money over the past year.
RXO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.6 | 6.3% above |
| 20 week MA | $24.6 | 15% above |
| 50 week MA | $20.4 | 38% above |
| 100 week MA | $18.9 | 49% above |
| 200 week MA | $20.6 | 37% above |
RXO has climbed back above all five of its weekly moving averages, and it's now 37% above its 200-week average.
RXO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $21.5 | $16.3 | -24% |
| 2023 | $16.3 | $23.3 | +43% |
| 2024 | $23.3 | $24.4 | +4.7% |
| 2025 | $24.4 | $12.7 | -48% |
| 2026 YTD | $12.7 | $28.3 | +123% |
RXO is up 123% so far in 2026, after finishing lower in two of the previous four years.